A new meta-analysis shows meaningful differences among FDA-approved antipsychotic adjuncts for MDD, with lumateperone showing the strongest efficacy and aripiprazole the best overall acceptability.

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the ...

Treatment with semaglutide significantly improves measures of motivation in patients with major depressive disorder (MDD), ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar depression. Clinical trials showed significant symptom improvement and potential ...

Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...

For many people with major depressive disorder (MDD), the first or second antidepressant doesn't cut it. Maybe your sleep gets better. Maybe the darkest thoughts ease up. But you still slog through ...

More than 21% of U.S. adults experience depression, greatly impacting their quality of life. Many people with ...